- Home
- MIRM vs MGNI Comparison
MIRM vs MGNI Comparison
Compare MIRM & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MGNI
- Stock Information
- Founded
- MIRM 2018
- MGNI 2007
- Country
- MIRM United States
- MGNI United States
- Employees
- MIRM N/A
- MGNI N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MGNI Computer Software: Programming Data Processing
- Sector
- MIRM Health Care
- MGNI Technology
- Exchange
- MIRM Nasdaq
- MGNI Nasdaq
- Market Cap
- MIRM 2.5B
- MGNI 2.4B
- IPO Year
- MIRM 2019
- MGNI N/A
- Fundamental
- Price
- MIRM $52.17
- MGNI $22.95
- Analyst Decision
- MIRM Strong Buy
- MGNI Strong Buy
- Analyst Count
- MIRM 9
- MGNI 13
- Target Price
- MIRM $66.22
- MGNI $22.00
- AVG Volume (30 Days)
- MIRM 413.0K
- MGNI 3.5M
- Earning Date
- MIRM 08-06-2025
- MGNI 08-06-2025
- Dividend Yield
- MIRM N/A
- MGNI N/A
- EPS Growth
- MIRM N/A
- MGNI N/A
- EPS
- MIRM N/A
- MGNI 0.21
- Revenue
- MIRM $379,251,000.00
- MGNI $674,622,000.00
- Revenue This Year
- MIRM $35.83
- MGNI $0.43
- Revenue Next Year
- MIRM $16.83
- MGNI $11.49
- P/E Ratio
- MIRM N/A
- MGNI $107.02
- Revenue Growth
- MIRM 69.31
- MGNI 5.59
- 52 Week Low
- MIRM $36.20
- MGNI $8.22
- 52 Week High
- MIRM $54.78
- MGNI $25.27
- Technical
- Relative Strength Index (RSI)
- MIRM 56.47
- MGNI 56.51
- Support Level
- MIRM $50.96
- MGNI $22.14
- Resistance Level
- MIRM $53.59
- MGNI $24.88
- Average True Range (ATR)
- MIRM 1.63
- MGNI 0.89
- MACD
- MIRM -0.17
- MGNI -0.36
- Stochastic Oscillator
- MIRM 53.06
- MGNI 29.56
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.